R
Rose V. Thomas
Researcher at National Institutes of Health
Publications - 14
Citations - 2427
Rose V. Thomas is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Pharmacokinetics & Zidovudine. The author has an hindex of 14, co-authored 14 publications receiving 2422 citations. Previous affiliations of Rose V. Thomas include University of Miami & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Phase i studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (azt)
Robert Yarchoan,Rose V. Thomas,Jean-Pierre Allain,Nanette McAtee,Richard Dubinsky,Hiroaki Mitsuya,Thomas J. Lawley,Bijan Safai,Charles E. Myers,Carlo Federico Perno,Raymond W. Klecker,Robert J. Wills,Margaret A. Fischl,M. Carol Mcneely,James M. Pluda,Michael Leuther,Jerry M. Collins,Samuel Broder +17 more
TL;DR: It is suggested that ddC has activity against HIV in vivo and has a different toxicity profile from that of zidovudine (AZT).
Journal ArticleDOI
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine
Robert Yarchoan,Hiroaki Mitsuya,Rose V. Thomas,James M. Pluda,Neil R. Hartman,Carlo Federico Perno,Kathy S. Marczyk,Jean-Pierre Allain,David G. Johns,Samuel Broder +9 more
TL;DR: Results suggest that serious short-term toxicity at therapeutic doses is not an inherent feature in the profile of agents with clinical anti-HIV activity and further controlled studies to define the safety and efficacy of this agent may be worth considering.
Journal ArticleDOI
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.
Raymond W. Klecker,Jerry M. Collins,Robert Yarchoan,Rose V. Thomas,Jean Jenkins,Samuel Broder,Charles E. Myers +6 more
TL;DR: N3TdR possesses pharmacokinetic properties that would facilitate the long‐term treatment of patients with acquired immunodeficiency syndrome: it can be given orally and it penetrates the central nervous system.
Journal ArticleDOI
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.
Robert Yarchoan,Robert Yarchoan,Pim Brouwers,Pim Brouwers,A. Robert Spitzer,A. Robert Spitzer,Jordan Grafman,Jordan Grafman,Jordan Grafman,Bijan Safai,Bijan Safai,Carlo Federico Perno,Carlo Federico Perno,Steven M. Larson,Steven M. Larson,G. Berg,G. Berg,Margaret A. Fischl,Margaret A. Fischl,Margaret A. Fischl,Alison Wichman,Alison Wichman,Rose V. Thomas,Rose V. Thomas,Arturo Brunetti,Arturo Brunetti,Peter J. Schmidt,Peter J. Schmidt,Charles E. Myers,Charles E. Myers,Samuel Broder,Samuel Broder +31 more
TL;DR: The hypothesis that certain AIDS-virus-associated neurological abnormalities are reversible by antiretroviral chemotherapy is supported.
Journal ArticleDOI
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
R. Yarchoan,James M. Pluda,Rose V. Thomas,Hiroaki Mitsuya,Pim Brouwers,Kathy Wyvill,Samuel Broder,N. R. Hartman,D. G. Johns +8 more
TL;DR: In this paper, the authors evaluated the long-term toxicity and activity profile of 2',3'-dideoxyinosine (ddl), a potent inhibitor of human immunodeficiency virus replication, in vitro.